Abstract: Current application relates to the field of neurodegenerative diseases. More specifically, the present invention relates to screening methods to identify compounds that can reduce the production of amyloidogenic Amyloid beta fragments. Said compounds can be used in treatments of for example Alzheimer's disease.

Abstract: A method and apparatus for the imaging of a labeled biological sample. The method comprises illuminating the labeled biological sample, generating members of a time series of images if the labeled biological sample, generating a plurality of difference images between later members of the time series of images of earlier members of the time series of images and combining the plurality of difference images to generate a final image of the labeled biological sample.

Abstract: The present invention relates to a population of monodisperse magnetic nanoparticles with a diameter between 1 and 100 nm which are coated with a layer with hydrophilic end groups. Herein the layer with hydrophilic end groups comprises an inner layer of monosaturated and/or monounsaturated fatty acids bound to said nanoparticles and bound to said fatty acids, an outer layer of a phospholipid conjugated to a monomethoxy polyethyleneglycol (PEG) comprising a hydrophilic end group, or comprises a covalently bound hydrophilic layer bound to said nanoparticles.

Abstract: The present invention relates to antibodies with a specificity for BACE1. More specifically, the invention provides monoclonal antibodies that bind to BACE1 and are capable of inhibiting the activity of BACE1 and methods producing these antibodies. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.

Abstract: The present invention relates to a population of monodisperse magnetic nanoparticles with a diameter between 1 and 100 nm which are coated with a layer with hydrophilic end groups. Herein the layer with hydrophilic end groups comprises an inner layer of monosaturated and/or monounsaturated fatty acids bound to said nanoparticles and bound to said fatty acids, an outer layer of a phospholipid conjugated to a monomethoxy polyethyleneglycol (PEG) comprising a hydrophilic end group, or comprises a covalently bound hydrophilic layer bound to said nanoparticles.

Abstract: The invention relates to the field of disorders of the peripheral or central nervous system, in particular, Alzheimer's disease, and the prevention and/or treatment thereof. In particular, the invention relates to ARF6 and/or ARF6 effector proteins as new targets in Alzheimer's disease, and based thereon, screening methods for compounds that reduce amyloid beta peptide formation in mammalian cells by affecting ARF6-mediated endosomal sorting.

Abstract: A method and apparatus for the imaging of a labeled biological sample. The method comprises illuminating the labeled biological sample, generating members of a time series of images if the labeled biological sample, generating a plurality of difference images between later members of the time series of images of earlier members of the time series of images and combining the plurality of difference images to generate a final image of the labeled biological sample.

Abstract: The invention relates to the field of disorders of the peripheral or central nervous system, in particular, Alzheimer's disease, and the prevention and/or treatment thereof. In particular, the invention relates to ARF6 and/or ARF6 effector proteins as new targets in Alzheimer's disease, and based thereon, screening methods for compounds that reduce amyloid beta peptide formation in mammalian cells by affecting ARF6-mediated endosomal sorting.

Abstract: The present invention relates to antibodies with a specificity for BACE1. More specifically, the invention provides monoclonal antibodies that bind to BACE1 and are capable of inhibiting the activity of BACE1 and methods producing these antibodies. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.

Abstract: The present invention relates to a population of monodisperse magnetic nanoparticles with a diameter between 1 and 100 nm which are coated with a layer with hydrophilic end groups. Herein the layer with hydrophilic end groups comprises an inner layer of monosaturated and/or monounsaturated fatty acids bound to said nanoparticles and bound to said fatty acids, an outer layer of a phospholipid conjugated to a monomethoxy polyethyleneglycol (PEG) comprising a hydrophilic end group, or comprises a covalently bound hydrophilic layer bound to said nanoparticles.

Abstract: The invention relates to the field of phagocytosis and more particularly to the field of neurons and neuron diseases. In particular the invention relates to the use of molecules capable of modulating the phagocytosis in neurons, more particularly to molecules modulating the activity of telencephalin.

Abstract: The present invention relates to the identification of the molecular binding domains between presenilins and its substrates such as amyloid precursor protein and telencephalin. These binding domains can be efficiently used in drug screening assays to screen for compounds capable of modulating the interaction between presenilins and type I transmembrane proteins. The invention further relates to compounds capable of modulating the interaction.

Abstract: The present invention relates to the identification of the molecular binding domains between presenilins and its substrates such as amyloid precursor protein and telencephalin. These binding domains can be efficiently used in drug screening assays to screen for compounds capable of modulating the interaction between presenilins and type I transmembrane proteins. The invention further relates to compounds capable of modulating the interaction.

Abstract: The present invention relates to the field of neurological and physiological dysfunctions associated with Alzheimer's disease, more particularly to mutant embryonic stem (ES) cell lines characterized by no detectable &ggr;-secretase activity, derived from double presenilin (PS 1 and PS 2) knockout mice embryos. These cell lines can be used for in vitro screening of molecules and products involved in regulated intramembrane proteolysis of proteins such as the PP, the APP-like proteins, Notch, Ire-1p, and other integral membrane proteins to identify proteases responsible for the latter proteolysis, like gamma-secretases, or proteins involved in the control of these proteolytic activities. These mutant ES cell lines can be manipulated to differentiate into fibroblasts, neurons, or myocytes or can be used to generate novel transgenic mice. Moreover, a reporter system comprising a chimeric molecule to detect the above-mentioned intramembrane proteolysis or modulators thereof has been developed.